SAN DIEGO, Feb. 9, 2017 /PRNewswire/ -- Arcturus Therapeutics, Inc. ("Arcturus" or the "Company"), a leading RNA medicines company, today announced that President & CEO Joseph E. Payne will present a corporate update at the 2017 Annual BIO CEO & Investor Conference on Monday, February 13th at 1:00 p.m. ET in the Park North room at the Waldorf Astoria Hotel in New York City.
Arcturus has several partnered and fully funded RNA therapeutics in its pipeline (including HBV, NASH, and orphan diseases), and is appraising investors interested in the Company's wholly owned rare disease messenger RNA programs. The management team will be available for one-on-one meetings with investors. To schedule a meeting, please use the BIO CEO One-on-One meeting portal.
About Arcturus Therapeutics, Inc.
Founded in 2013 and based in San Diego, Arcturus Therapeutics, Inc. is an RNA medicines company with enabling technologies — UNA Oligomer chemistry and LUNAR™ nanoparticle delivery. Arcturus' versatile RNA therapeutics platform can be applied toward all types of RNA medicines including small interfering RNA, messenger RNA, antisense RNA, microRNA and gene editing therapeutics. The company owns LUNAR™ nanoparticle delivery and unlocked nucleomonomer agent (UNA) technology including UNA Oligomers, which are covered by its patent portfolio (80 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' proprietary UNA technology can be used to target any gene in the human genome, as well as viral genes, and other species for therapeutic purposes. The Company's commitment to the development of novel RNA therapeutics has led to significant partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and Takeda Pharmaceutical Inc. For more information, visit www.ArcturusRx.com.
SOURCE Arcturus Therapeutics, Inc.